0000950170-23-046889.txt : 20230907 0000950170-23-046889.hdr.sgml : 20230907 20230907083931 ACCESSION NUMBER: 0000950170-23-046889 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230904 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230907 DATE AS OF CHANGE: 20230907 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 231241042 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 8-K 1 crsp-20230904.htm 8-K 8-K
false000167441600-000000000016744162023-09-042023-09-04

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 4, 2023

 

 

CRISPR THERAPEUTICS AG

(Exact name of Registrant as Specified in Its Charter)

 

 

Switzerland

001-37923

Not Applicable

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

Baarerstrasse 14

 

6300 Zug, Switzerland

 

Not Applicable

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 41 (0)41 561 32 77

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares, nominal value CHF 0.03

 

CRSP

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 7, 2023, CRISPR Therapeutics AG (the “Company”) announced that Rodger Novak, M.D. tendered his resignation as President of the Company as well as a director and Chairman of the Company’s Board of Directors (the “Board”), and all such resignations to be effective as of September 15, 2023 (the “Resignation Date”). Dr. Novak indicated that such resignations were not the result of any dispute or disagreement with the Company or the Company’s Board on any matter relating to the operations, policies or practices of the Company.

Item 8.01 Other Events.

In connection with Dr. Novak’s resignation from the Board, the Board appointed Samarth Kulkarni, Ph.D., the Company’s Chief Executive Officer and a current member of the Board, as Chairman of the Board, effective as of the Resignation Date, and Dr. Kulkarni shall serve in such capacity for a term ending at the next annual general meeting of the Company’s shareholders. Dr. Kulkarni’s compensation arrangement with the Company will remain unchanged.

The full text of the press release announcing Dr. Novak’s resignation and Dr. Kulkarni’s appointment as Chairman is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit
No.

 

Description

 

 

99.1

Press Release by CRISPR Therapeutics AG, dated September 7, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

CRISPR Therapeutics AG

 

 

 

 

Date:

 September 7, 2023

By:

/s/ Samarth Kulkarni

 

 

 

Samarth Kulkarni, Ph.D.
Chief Executive Officer

 

 

 

 EX-99.1 2 crsp-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

CRISPR Therapeutics Announces Leadership Transition

-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023-

-Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company-

 

ZUG, Switzerland and Boston, Mass., September 7, 2023 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics, has elected to leave CRISPR Therapeutics after nearly a decade of dedicated service to the Company. Dr. Novak’s departure will be effective as of September 15, 2023. As of that date, Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, will succeed Dr. Novak as Chairman of the Board of CRISPR Therapeutics and will continue serving as CEO of the Company.

“Since co-founding CRISPR Therapeutics nearly 10 years ago, Rodger has played a critical role in charting the growth of the company, first as CEO, and subsequently as the Chairman of the Board,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “He was instrumental in defining the business model of the company in its early days, establishing key collaborations, and shepherding the initial public offering and the early-stage development of exa-cel, our investigational therapy for severe sickle cell disease and transfusion-dependent beta thalassemia currently under regulatory review for commercial use. On behalf of my fellow board members, I want to thank Rodger for being a mentor to me and the management team, and for his dedicated commitment to CRISPR over the years.”

“I am proud of the rapid innovation and the strong execution at CRISPR Therapeutics over the last few years, which have positioned us as the pre-eminent gene editing company and brought us to the cusp of what could be the first approval for a CRISPR-based medicine,” said Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics. “It has been extremely gratifying to be part of this journey. Having been with the company since inception and working closely with Sam for the past eight years, I am very happy to pass the baton to Sam, who has had a pivotal role in building CRISPR Therapeutics.”

 

“On behalf of the entire Board, I want to thank Rodger for his leadership in guiding the company during a critical time in its journey,” said Douglas Treco, Ph.D., Lead Independent Director of the CRISPR Therapeutics Board. “With outstanding management and a strong innovation engine, the Board is confident that CRISPR Therapeutics is on the right path to creating long-term value for shareholders and patients and continuing as the global leader in gene editing.”

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based

 

in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:

Susan Kim

+1-617-315-4600

susan.kim@crisprtx.com

Media Contact:

Rachel Eides

+1-617-315-4493

rachel.eides@crisprtx.com

 EX-101.SCH 3 crsp-20230904.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 crsp-20230904_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre Commencement Issuer Tender Offer Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key Entity Tax Identification Number Entity Registrant Name Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Pre Commencement Tender Offer Cover [Abstract] Security Exchange Name Entity Emerging Growth Company Amendment Flag Securities Act File Number Entity Address, Address Line One Security 12b Title Entity Address, Country Document Type EX-101.PRE 5 crsp-20230904_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Sep. 04, 2023
Cover [Abstract]  
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001674416
Document Type 8-K
Document Period End Date Sep. 04, 2023
Entity Registrant Name CRISPR THERAPEUTICS AG
Entity Incorporation, State or Country Code V8
Securities Act File Number 001-37923
Entity Address, Address Line One Baarerstrasse 14
Entity Address, Postal Zip Code 6300
Entity Address, City or Town Zug
Entity Address, Country CH
City Area Code 41 (0)41
Local Phone Number 561 32 77
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Shares, nominal value CHF 0.03
Trading Symbol CRSP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 crsp-20230904_htm.xml IDEA: XBRL DOCUMENT 0001674416 2023-09-04 2023-09-04 false 0001674416 00-0000000 8-K 2023-09-04 CRISPR THERAPEUTICS AG V8 001-37923 Baarerstrasse 14 6300 Zug CH 41 (0)41 561 32 77 false false false false Common Shares, nominal value CHF 0.03 CRSP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .]$)U<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #O1"=7#YKTKN\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*'&@HR;U9:6G#08K;.QF9+4UBQ-C:R1]^R59FS*V!]C1TN]/ MGT U!H5=I.?8!8KL*-T-OFF3PK 1)^:@ !*>R)N4CXEV;!ZZZ V/SWB$8/## M' ED4:S $QMKV, $S,)"%+JVJ#"2X2Y>\!87?/B,S0RS"-20IY83E'D)0D\3 MPWEH:K@!)AA3].F[0'8ASM4_L7,'Q"4Y)+>D^K[/^VK.C3N4\/;T^#*OF[DV ML6F1QE_)*3X'VHCKY-?J8;O?"2T+667%.BON]Z54U5K)U?OD^L/O)NP[ZP[N M'QM?!74-O^Y"?P%02P,$% @ [T0G5YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #O1"=7AZBF(% $ ",$ & 'AL+W=O)4#YVM,=FMZ^IPRQ.FKV3& M4_AF+57"#-RJC:LSQ5E4=$IBU_>\KILPD3JC0?%LID8#F9M8I'RFB,Z3A*G] M'8_E;NA0Y^W!7&RVQCYP1X.,;?B"FZ_93,&=6ZE$(N&I%C(EBJ^'SIC>WOF! M[5"T^";X3A]=$SN4E90_[)>(Q#XV58/#QPB<\CJT2^&% UU8OE+$N_I-=V38( M'!+FVLCDT!D($I&6G^SU$(BC#IW^B0[^H8-?<)ACD$V1"61N0A-<+LR30M9QNB-G -O,0V=<.# MX%TIZ)\07/#LBGC!!?$]O_/_[BZP58!^!>@7>IT3>A/YPA7Y9[S21L$4_MM$ M5"H$S0HVKV]UQD(^="!Q-5G\A?)V*KX.ICPXQ6[)7,HT@D&(M MPB)TY#E/5EPU\>**GG?IE7\(7E#A!:C8&"8W*B;X,6:;)AB\_YK%FB,^;R+"E2 NM-L+ MI%L+H55A<5J])_N<]X$PO>O7_Y M$8'H51"]\R!F7 EIRS B4,R-/+A247Q%];657[]BZY\S;W.^$;8 ?*9)8UD MN,YD/EW,YF3Y]# ?SQZ^+J>3!1E_0 !O*L";A=D82!^1"HR MD3ED'"2>C!JIK7'>BW3$N9*&,$U&8=0B2+FB#NTB$'Z7W9Z-^CL MTB/[I^>$;QQ%8(WZXNV"?()VY$O:&+,6R3O&%%VNPI;L@SQ8OP\#3DY;H-VQO8'WY9KT], M(*[71N;7'N_CMOR.;*IU#F1M@"VRK8"UT_NX+1\6H3VA_HHLA8D;2[!%Q(X0 MMK:++5@\>$HJX4@"9?3"XAR&__1(O"L/W?4?;?MQ>UXJ%MFT6^R3E6Q,NA:! MR7PQPTAJ?_=Q0ZX"]_ :;EFZX2>W0"U"S^/%_?AOC*DV=_\L<00W8!O#]6DKS=F-/L-4/$*/_ %!+ P04 " #O1"=7GZ ;\+$" M #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+3 M8JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A M8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72L MJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GT MA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WAT MUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:I MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 M]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NX MZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8; M9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%' MGL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G M)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 M" #O1"=7EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q="> M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C] M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA< MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X M4$L#!!0 ( .]$)U<<.&7J/P$ #P" / >&PO=V]R:V)O;VLN>&UL MC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=15*1>>O)Z M;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU!,:F&H"] MRZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T M> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+ M8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.(<_I/C+&J ML(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W\!J-'[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E* M%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,) MKM\,<'AT_@%02P,$% @ [T0G5V60>9(9 0 SP, !, !;0V]N=&5N M=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2 MVS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\ MFK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9 MHS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM M0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I- M"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O& M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " #O1"=7!T%-8H$ M "Q $ @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 M Q0 ( .]$)U97)PC$ 8 )PG 3 M " &UL4$L! A0#% @ M[T0G5X>HIB!0! C! !@ ("!#@@ 'AL+W=O&UL4$L! A0#% @ [T0G5Y>* MNQS $P( L ( !< \ %]R96QS+RYR96QS4$L! A0# M% @ [T0G5QPX9>H_ 0 / ( \ ( !61 'AL+W=O M7!E&UL4$L%!@ ) D /@( /03 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports crsp-20230904.htm crsp-20230904.xsd crsp-20230904_lab.xml crsp-20230904_pre.xml crsp-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "crsp-20230904.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "crsp-20230904.htm" ] }, "labelLink": { "local": [ "crsp-20230904_lab.xml" ] }, "presentationLink": { "local": [ "crsp-20230904_pre.xml" ] }, "schema": { "local": [ "crsp-20230904.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "crsp", "nsuri": "http://www.crisprtx.com/20230904", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "crsp-20230904.htm", "contextRef": "C_62e81ba2-4718-407b-bff0-bacb6961e989", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "crsp-20230904.htm", "contextRef": "C_62e81ba2-4718-407b-bff0-bacb6961e989", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.crisprtx.com/20230904/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-046889-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-046889-xbrl.zip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�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